Hypnotic and Antiepileptic Effects of Cannabidiol
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Clinical trials with cannabidiol (CBD) in healthy volunteers, insomniacs, and epileptic patients conducted in the authors' laboratory from 1972 up to the present are reviewed. Acute doses of cannabidiol ranging from 10 to 600 mg and chronic administration of 10 mg for 20 days or 3 mg/kg/day for 30 days did not induce psychologic or physical symptoms suggestive of psychotropic or toxic effects; however, several volunteers complained of somnolence. Complementary laboratory tests (EKG, blood pressure, and blood and urine analysis) revealed no sign of toxicity. Doses of 40, 80, and 160 mg cannabidiol were compared to placebo and 5 mg nitrazepam in 15 insomniac volunteers. Subjects receiving 160 mg cannabidiol reported having slept significantly more than those receiving placebo; the volunteers also reported significantly less dream recall with the three doses of cannabidiol than with placebo. Fifteen patients suffering from secondary generalized epilepsy refractory to known antiepileptic drugs received either 200 to 300 mg cannabidiol daily or placebo for as long as 4.5 months. Seven out of the eight epileptics receiving cannabidiol had improvement of their disease state, whereas only one placebo patient improved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients
Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R., Sanvito, W. L., Lander, N., & Mechoulam, R. (2008) · Pharmacology · doi:10.1159/000137430 · Cited by 568
Self-citationConsroe, P., & Wolkin, A. (1977) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30824-4 · Cited by 152
Toward drugs derived from cannabis
Mechoulam, R., & Carlini, E. A. (1978) · Die Naturwissenschaften · doi:10.1007/bf00450585 · Cited by 140
Self-citationThe anticonvulsant activity of cannabidiol and cannabinol
Karler, R., Cely, W., & Turkanis, S. A. (1973) · Life Sciences · doi:10.1016/0024-3205(73)90141-0 · Cited by 131
Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents
Carlini, E. A., Leite, J. R., Tannhauser, M., & Berardi, A. C. (1973) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1973.tb10660.x · Cited by 125
Self-citationCousens, K., & DiMascio, A. (1973) · Psychopharmacology · doi:10.1007/bf00437513 · Cited by 92
CHESHER, G. B., & Jackson, D. M. (1974) · Psychopharmacology · doi:10.1007/bf00421539 · Cited by 84
Hypnoticlike effects of cannabidiol in the rat
Monti, J. M. (1977) · Psychopharmacology · doi:10.1007/bf00497858 · Cited by 84
Hartmann, E. L., Chung, R., & Chien, C.-P. (1971) · Psychopharmacology · doi:10.1007/bf00402635 · Cited by 67
Hypnotics — Methods of development and evaluation
Rawlins, M. (1977) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(77)90049-1 · Cited by 66
Antiepileptic and Prophylactic Effects of Tetrahydrocannabinols in Amygdaloid Kindled Rats
Corcoran, M. E., McCaughran, J. A., & Wada, J. (1978) · Epilepsia · doi:10.1111/j.1528-1157.1978.tb05011.x · Cited by 63
Interaction of cannabidiol and alcohol in humans
Consroe, P. F., Carlini, E. A., Zwicker, A. P., & de Lacerda, L. A. (1979) · Psychopharmacology · doi:10.1007/bf00431988 · Cited by 63
Self-citationSUBACUTE CANNABINOID TREATMENT: ANTICONVULSANT ACTIVITY AND WITHDRAWAL EXCITABILITY IN MICE
Karler, R., & Turkanis, S. A. (1980) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1980.tb14562.x · Cited by 56
Antiepileptic and Prophylactic Effects of Tetrahydrocannabinols in Amygdaloid Kindled Cats*
Wada, J., Wake, A., Sato, M., & Corcoran, M. E. (1975) · Epilepsia · doi:10.1111/j.1528-1157.1975.tb06080.x · Cited by 51
Anticonvulsant activity of Δ9-tetrahydrocannabinol compared with three other drugs
Sofia, R. D., Solomon, T. A., & Barry, H. (1976) · European Journal of Pharmacology · doi:10.1016/0014-2999(76)90295-8 · Cited by 44
CHESHER, G. B., Jackson, D. M., & Malor, R. (1975) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1975.tb09515.x · Cited by 40
Anticonvulsant activity of four oxygenated cannabidiol derivatives.
Carlini, E. A., Mechoulam, R., & Lander, N. (1975) · PubMed · Cited by 39
Self-citationCannabidiol and phenytoin: a structural comparison
Tamir, I., Mechoulam, R., & Meyer, A. Y. (1980) · Journal of Medicinal Chemistry · doi:10.1021/jm00176a022 · Cited by 31
MARIHUANA AND EPILEPSY: PARADOXICAL ANTICONVULSANT AND CONVULSANT EFFECTS
Feeney, D. M. (1979) · Elsevier eBooks · doi:10.1016/b978-0-08-023759-6.50053-6 · Cited by 30
Possivel efeito hipnotico do canabidiol no ser humano. Estudo preliminar
Carlini, E. A., Masur, J., & Magalhaes, C. C. P. (1979) · Ciência e Cultura · Cited by 7
Self-citation
Cited by
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535
Agonistic properties of cannabidiol at 5-HT1a receptors
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878
The effects of cannabinoids on the brain
Ameri, A. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00087-2 · Cited by 812
Cannabidiol: State of the art and new challenges for therapeutic applications
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M. C., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 614
Russo, E., & Guy, G. W. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.08.026 · Cited by 610
Metadata
- Authors
- CARLINI, E. A., & CUNHA, J. M.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 1981-08-09
- Volume
- 21
- Issue
- S1
- Pages
- 417S-427S
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W1981441554
- Cited by
- 277
- References
- 20
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.